View in EDS

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Saved in:
Bibliographic Details
Title: Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Authors: Rudin, Charles M1 rudinc@mskcc.org, Pietanza, M Catherine1, Bauer, Todd M2,3, Ready, Neal4, Morgensztern, Daniel5, Glisson, Bonnie S6, Byers, Lauren A6, Johnson, Melissa L2,3, IIIBurris, Howard A2,3, Robert, Francisco7, Han, Tae H8, Bheddah, Sheila8, Theiss, Noah9, Watson, Sky9, Mathur, Deepan9, Vennapusa, Bharathi9, Zayed, Hany8, Lally, Satwant8, Strickland, Donald K3, Govindan, Ramaswamy5
Source: Lancet Oncology. Jan2017, Vol. 18 Issue 1, p42-51. 10p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(16)30565-4